[Traitement] Efficacité du tacrolimus dans le traitement de la MG et influence sur les sous-ensembles lymphocytaires.
Posté : 13 juin 2019 12:25
Lu sur : https://www.ncbi.nlm.nih.gov/pubmed/30293884
Traduction disponible directement en cliquant en bas à droite de ce message sur l'expression Traduire en
Rev Neurol (Paris). 2019 Jan - Feb;175(1-2):65-72. doi: 10.1016/j.neurol.2018.01.377. Epub 2018 Oct 4.
Clinical efficacy of tacrolimus for treating myasthenia gravis and its influence on lymphocyte subsets.
Bao J1, Gao S2, Weng Y1, Zhu J3, Ye H4, Zhang X5.
This study aimed to determine the clinical efficacy and effects of tacrolimus in treating myasthenia gravis (MG).
A total of 45 outpatients and inpatients were divided into a tacrolimus group (n=15) and non-tacrolimus group (n=30): those in the former group were treated with 3mg/day of tacrolimus for 24 weeks, while those in the latter (control) group took other immunosuppressants (prednisone, azathioprine combined with prednisone). Each group was evaluated at weeks 4, 8, 12, 16, 20 and 24 by Myasthenia Gravis Foundation of America Quantitative Myasthenia Gravis (MGFA-QMG) Test, activities of daily living (ADL) profiles, and manual muscle (MMT) and fatigue tests. Dynamic changes in CD4+CD25+high cells were tested by flow cytometry. Inflammatory cytokines were also evaluated in the tacrolimus group.
Efficacy index scores decreased significantly compared with baseline at every test week in both groups (P<0.01), although improvements were more evident with than without tacrolimus treatment (F=9.312, P<0.01 vs. F=24.551, P<0.01 and F=10.710, P<0.01). At week 24, peripheral blood CD4+CD25+high T cells with tacrolimus decreased significantly (P<0.01), but increased significantly without tacrolimus (P<0.01). During treatment, CD19+BAFF-R B cells in peripheral blood decreased in both groups (P<0.05). Interferon (IFN)-γ concentrations in peripheral blood also diminished significantly with tacrolimus (P<0.01).
A relatively low dose of tacrolimus can affect multiple immune-system targets and, thus, can treat MG effectively in terms of both clinical symptoms and immunological responses.
Sur demande de nos donateurs, nous pouvons faire l'acquisition d'un tiré-à-part de l'article intégral
Le coût de 27,00€ est pris en charge par l'Association